Review

Acute Kidney Injury in the Patient with Cancer

Alejandro Meraz-Munoz 1, Amit Langote 2, Kenar D. Jhaveri 3, Hassane Izzedine 4 and Prakash Gudsoorkar 5,*

1 Division of Nephrology, Department of Medicine, St Michael's Hospital, Toronto, ON M5B 1W8, Canada; Alejandro.Meraz-Munoz@unityhealth.to
2 Consultant Nephrologist, Apollo Hospital, Navi Mumbai, Maharashtra 400614, India; drlangoteamit@gmail.com
3 Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine, Great Neck, NY 11021, USA; Kjhaveri@northwell.edu
4 Department of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, 75013 Paris, France; h.izzedine@ramsaygds.fr
5 Division of Nephrology & Kidney Clinical Advancement, Research & Education Program, University of Cincinnati, Cincinnati, OH 45267, USA

* Correspondence: gudsoops@ucmail.uc.edu; Tel.: +1-513-558-5471

Abstract: Over the last three decades, advancements in the diagnosis, treatment, and supportive care of patients with cancer have significantly improved their overall survival. However, these advancements have also led to a higher rate of cancer-related complications. Acute kidney injury (AKI) and chronic kidney disease (CKD) are highly prevalent in patients with cancer, and they are associated with an increased risk of all-cause mortality. This bidirectional interplay between cancer and kidney, termed “the kidney–cancer connection” has become a very active area of research. This review aims to provide an overview of some of the most common causes of AKI in patients with cancer. Cancer therapy-associated AKI is beyond the scope of this review and will be discussed separately.

Keywords: acute kidney injury (AKI); kidney replacement therapy (KRT); thrombotic microangiopathy (TMA); hematopoietic stem cell transplant (HSCT); tumor lysis syndrome (TLS)

1. Introduction

The last two decades have seen an exponential rise in the number of drugs used in cancer therapy. With precision medicine, novel targeted therapies, and better supportive care, the life expectancy of patients with cancer has improved [1]. Unfortunately, acute kidney injury (AKI) in the context of cancer has been increasingly recognized. Overall, AKI in cancer patients can be broadly classified as pre-renal or hemodynamic, intrinsic, and obstructive nephropathy. Nevertheless, malignancy adds a layer of complexity since AKI may be a direct complication of cancer itself (infiltration, paraneoplastic syndrome), cancer-related metabolic disturbances (hypercalcemia, tumor-lysis syndrome), anti-cancer therapy (chemotherapy, immune checkpoint inhibitors, stem-cell transplant) or other related complications (hypovolemia, infections, sepsis) (Figure 1).
2. Epidemiology of AKI in Patients with Cancer

Several different studies have defined the incidence of AKI related to cancer. Christiansen et al. described the incidence of AKI in all incident cancer patients in a population-based study in Denmark \( (n = 44,116) \). The risk of developing AKI criteria was 17.5% during the first year and up to 27% during the first five years of cancer diagnosis \[1\]. A population-based study from Ontario, Canada, reported a cumulative incidence of AKI of 9.3% \[2\]. Similarly, a population-based study from China reported an incidence of AKI in patients with cancer of 7.5% \[3\]. The malignancies most frequently associated with AKI are multiple myeloma, kidney, liver, bladder and lymphoma and leukemia \[4–9\]. The risk factors for developing AKI are cancer stage, previous chronic kidney disease (CKD), diabetes mellitus and use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) \[10\]. Moreover, AKI in hospitalized patients has been linked to an increased length of hospital stay and costs of care \[5,6\].

3. Acute Kidney Injury in Critically Ill Patients with Cancer

Acute kidney injury occurs in 50–60% of patients admitted to the intensive care unit, and 20% of those patients have an underlying malignancy \[7\]. The frequency of AKI and kidney replacement therapy (KRT) has increased over the past couple of decades, perhaps due to better survival and a higher admission rate of patients with cancer to the intensive care units \[1,8,9\]. Critically ill patients with cancer are exceptionally susceptible to AKI, and the incidence of requiring KRT varies from 8–13% in patients with solid tumors and 10–34% in patients with hematological malignancies \[10\]. The risk of developing AKI is more significant in patients with septic shock, exposure to nephrotoxins, obstructive nephropathy and hematological malignancies, especially multiple myeloma \[3,10–12\]. The short-term mortality of critically ill patients with cancer and severe AKI is comparable to critically ill patients without cancer \[13,14\]. In a cohort of critically ill patients with cancer \( (n = 975) \), the in-hospital and six-month mortality of AKI requiring KRT was 64% and 73%, respectively \[12\]. The need for KRT entails high mortality, and for patients who are not dialysis candidates, palliative care consult services can be helpful.
4. Hemodynamic Causes of Acute Kidney Injury in Patients with Cancer

Patients with cancer are susceptible to a myriad of hemodynamic insults. Oncology patients experience anorexia, nausea and vomiting in 60–80% of the cases [15]. A careful physical examination looking for signs of volume contraction should always be performed. Nonetheless, the sensitivity and specificity of physical examination are low. Initial investigations should include serum electrolytes, urea or blood urea nitrogen, and creatinine levels. A point of care ultrasound can further inform our evaluation in differentiating hypovolemia from other causes of AKI [16–18].

Hypercalcemia complicates up to 30% of all malignancies and causes AKI by several mechanisms [19]. Hypercalcemia leads to severe volume depletion via the activation of the calcium sensor located in the thick ascending loop of Henle, causing a furosemide-like effect [20]. Hypercalcemia leads to the vasoconstriction of the afferent arteriole, decreasing intra-glomerular pressure [21]. Finally, the precipitation of calcium phosphate crystals and clogging of the tubules have been described [22]. The initial treatment should be directed to restore intravascular volume with crystalloids (intravenous normal saline 200–250 mL/Hr). Loop diuretics are reserved for patients with volume overload. Anuric patients may become fluid overloaded rapidly and be unresponsive to diuretics; hence hemodialysis with low calcium baths should be performed in these cases. Calcitonin or bisphosphonates are indicated after the initial resuscitation [23]. The preferred bisphosphonates are pamidronate and ibandronate; however, zoledronic acid may be superior and has been used successfully in patients with serum Cr <4.5 mg/dL with a similar safety profile [24]. Zoledronic acid is not recommended for chronic use in patients with an estimated glomerular filtration rate of eGFR <30 mL/min/m² [25]. Denosumab, a neutralizing monoclonal antibody directed against the receptor activator of nuclear factor kb ligand, has been used for the treatment of cancer-related hypercalcemia [26,27].

Contrast-associated acute kidney injury (CA-AKI) has been often cited as a common cause of AKI [28]. However, the relevance and causal relationship between contrast medium and intrinsic AKI have been questioned [29]. The use of iso-osmolar and low-osmolar contrast agents in low quantities has improved these procedures’ safety [30]. The rise in serum creatinine associated with contrast may be explained by intraglomerular hemodynamic changes rather than intrinsic tubular damage [31,32]. In patients with an estimated glomerular filtration rate (eGFR) of >45 mL/min/m², the risk of AKI is negligible. Caution is advised in patients with a lower eGFR who also have other risk factors for CA-AKI. For these patients, prophylactic IV fluids are advised [33].

Heart failure (HF) is another hemodynamic derangement commonly encountered in patients with cancer. Besides the common causes of HF, it is essential to inquire about previous exposure to cardiotoxic chemotherapy such as anthracyclines (doxorubicin, daunorubicin, and epirubicin) and the human epidermal growth factor receptor 2 (HER2) modulator trastuzumab [34]. Type 1 cardiorenal syndrome is the result of a decreased eGFR secondary to kidney hypoperfusion. Low cardiac output and intra-renal venous congestion are the main drivers of this pathological condition. Maladaptive neurohormonal changes such as the upregulation of the renin–angiotensin–aldosterone system (RAAS), the non-osmotic release of vasopressin and the sympathetic nervous system’s activation result in increased sodium and water reabsorption [35,36]. Decongestion with a loop diuretic alone or in combination with other classes of diuretics are the first step in treating this pathology [37].

Liver injury or cirrhosis are associated with hepatorenal syndrome (HRS), a diagnosis of exclusion. Portal hypertension causes nitric oxide-mediated splanchnic vasodilation, with secondary pooling of blood in the splanchnic circulation and hypotension. Similarly, the activation of RAAS and other neurohumoral systems leads to kidney vasoconstriction, hypoperfusion, and the retention of salt and water. Management includes treating HRS precipitants and restoring effective arterial circulation with vasopressors: terlipressin, norepinephrine or midodrine in combination with octreotide [38].

Tense ascites may increase intraabdominal pressure, causing abdominal compartmental syndrome. Paracentesis with albumin replacement may improve kidney hemodynamics
and help alleviate AKI [39]. The sinusoidal obstruction syndrome, a complication of stem-cell transplant, is similar to hepatorenal syndrome due to the associated portal hypertension secondary to the hepatic sinusoidal injury.

5. Cancer-Associated Thrombotic Microangiopathy (TMA)

Cancer-associated thrombotic microangiopathy (TMA) refers to a constellation of disorders characterized by microvascular thrombosis, thrombocytopenia, and resultant ischemia of the end organ affected, e.g., kidney and brain [40]. The pathological characteristics of TMA include intrarenal or systemic microvascular thrombosis with endothelial swelling and microvascular obstruction (Figure 2) [41].

![Figure 2. Mechanisms causing TMA in patients with cancer. ADAMTS-13 = a disintegrin and metalloproteinase with thrombospondin type-1 motif, member 13, PDGF = platelet derived growth factor. VEGF = vascular endothelial growth factor, RBC = red blood cell, RES = reticuloendothelial system.](image)

TMA syndromes are a complication of cancer itself and can also occur as a side effect of cancer chemotherapeutic agents [42]. One of the earliest reported studies on TMA in cancer patients is from 1972 from Germany, which showed 5.7% of patients with metastatic cancer have TMA [43]. Gastric carcinoma tops the list (50%), followed by breast and lung carcinoma (Table 1).

5.1. Differentiating Cancer-Associated TMA and Cancer Chemotherapy-Induced TMA

In oncological practice, one must differentiate between cancer-associated and chemotherapy-induced TMA. In some cases, it is very challenging to delineate the two. Table 2 outlines some key differences between the two processes.
Table 1. Cancers associated with TMA [44–49].

| System                           | Cancers                                                                 |
|----------------------------------|-------------------------------------------------------------------------|
| **Gastrointestinal Tract**       |                                                                         |
| Gastric Cancer                   |                                                                         |
| Colon Cancer                     |                                                                         |
| Carcinoma of the Anal Canal (Squamous Cell Carcinoma) | |
| Metastatic Appendiceal Carcinoma |                                                                         |
| **Lung**                         |                                                                         |
| Adenocarcinoma                   |                                                                         |
| Squamous Cell Carcinoma          |                                                                         |
| Small Cell Lung Carcinoma        |                                                                         |
| **Genitourinary Tract**          |                                                                         |
| Prostate Cancer                  |                                                                         |
| Ovarian Cancer                   |                                                                         |
| Renal Cell Carcinoma             |                                                                         |
| Seminal Vesicle Tumor.           |                                                                         |
| **Hepatobiliary System**         |                                                                         |
| Hepatocellular Carcinoma         |                                                                         |
| Pancreatic Cancer                |                                                                         |
| Cholangiocarcinoma               |                                                                         |
| **Endocrine System**             |                                                                         |
| Multiple Endocrine Neoplasia Type 1 |                                                                 |
| Pheochromocytoma                 |                                                                         |
| Neuroendocrine Tumor             |                                                                         |
| Prolactin-Producing Pituitary Adenoma |                                                      |
| **Hematologic Malignancies**     |                                                                         |
| Non-Hodgkin Lymphoma             |                                                                         |
| Acute Lymphoblastic Leukemia     |                                                                         |
| Myelodysplastic Syndrome         |                                                                         |
| Hodgkin Lymphoma                 |                                                                         |
| Multiple Myeloma                 |                                                                         |
| **Others**                       |                                                                         |
| Breast Cancer                    |                                                                         |
| Kaposi Sarcoma                   |                                                                         |
| Carcinoma of Unknown Origin      |                                                                         |

Table 2. Key differences between cancer-related and chemotherapy-related TMA [46,50–53]. TTP: thrombotic thrombocytopenic purpura.

| Features                        | Cancer-Associated TMA                                      | Chemotherapy-Induced TMA                                           |
|---------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------|
| Metastatic Disease              | 90% Have Metastatic Disease                               | May not be Present.                                               |
| Clinical Phenotype              | TTP-Like Phenotype in Approximately 6% of Patients        | The Spectrum Ranges from Typical HUS to Kidney Limited TMA        |
| Disseminated Intravascular Coagulation | Present in 15% of Patients | Absent                                                              |
| Blood Picture                   | Carcinocythemia (Carcinoma Cell Leukemia) is Associated with TMA Seen on Peripheral Blood Film in Disseminated Solid Organ Malignancies Leucoerythroblastic with More Significantly Elevated Serum LDH Levels | These Phenomena May or May not Occur                              |
| Mean Age                        | 56 Years                                                  | 40 Years                                                          |
| Symptoms                        | Progressive Weakness, Weight Loss and Pain. The Median Duration of Symptoms is 21 Days | The Median Duration of Symptoms is 8 Days                         |
| Therapy                         | Fail to Respond to Plasmapheresis                         | Those with ADAMTS13 Deficiency Especially Respond to Plasmapheresis |

HUS = Hemolytic Uremic Syndrome, LDH = Lactate Dehydrogenase.
5.2. Treatment of Cancer-Associated TMA

In general, plasma exchange is more effective than plasma infusion in treating thrombotic thrombocytopenic purpura (TTP) because its pathogenesis is mediated by ultra-large Von Willebrand Factor (VWF) multimers and autoantibodies to a disintegrin and metalloprotease with thrombospondin type-1 motif, member 13 (ADAMTS-13). These mediators are at least partially removed by plasma exchange [54]. Cancer-associated TMA responds poorly to plasma exchange, most likely due to the lack of severe deficiency of ADAMTS-13 [55]. Cancer-associated TMA has been observed to improve with the control of the underlying cancer [56].

6. Acute Kidney Injury Due to Renal Parenchymal Invasion/Infiltrative Malignancies

Many solid and hematological cancers may involve the renal parenchyma. Lymphomas and leukemias are the most common cancers that demonstrate autopsy evidence of infiltration, with the incidence being 6% to 60% [57,58]. Lymphomatous invasion of the kidneys (LIK) can present as acute kidney injury, new-onset or worsening proteinuria and hematuria; however, diagnosis is usually incidental. In approximately one percent of cases, the tumor burden infiltrating the kidneys can be so high that it can lead to AKI [59,60]. Tornroth et al. demonstrated various pathological phenotypes of lymphomatous invasion of kidneys [61]. Most cases (87%) showed interstitial infiltration followed by intraglomerular infiltration (45%). Renal imaging in these cases shows bulky and enlarged kidneys. A high index of suspicion is necessary to prompt a kidney biopsy. Another case series showed that 34% of non-Hodgkin’s lymphoma developed parenchymal kidney invasion; however, only 14% were diagnosed before death [62]. For indolent hematological cancers such as chronic lymphocytic leukemia, which are often not treated unless there is end-organ involvement, the demonstration of LIK may often pull the trigger to initiate chemotherapy. The most common solid organ cancers metastasizing to the kidneys are lung carcinoma, gastric, breast and malignant melanoma [11]. Renal metastases usually manifest as bilateral, small, multifocal parenchymal nodules, though single exophytic lesions have also been described [63]. Metastases to kidneys are seen in a setting of massive tumor burden and portend a poor prognosis. Acute kidney injury from infiltrative cancers results from renal parenchymal compression, which leads to the disruption of the glomerular, tubulointerstitial and microvascular architecture, leading to impairment of the GFR. Most cases are subclinical; however, patients may present with hypertension (the upregulation of the renin–angiotensin axis), flank pain (due to stretching of renal capsule) and hematuria.

7. Hematopoietic Stem Cell Transplant-Related Acute Kidney Injury

Acute kidney injury after hematopoietic stem cell transplant (HSCT) is usually defined as a doubling of baseline serum creatinine or decline in GFR of at least 50% within the first 100 days after engraftment [64]. It was difficult to determine the epidemiology of HSCT-related AKI due to inconsistencies in the AKI definition. Hence, an attempt was made to develop uniformity to gain insight into the epidemiology of AKI and facilitate the comparison of studies. Recent studies have used criteria such as the risk, injury, failure, loss of kidney function, end-stage kidney disease (RIFLE) system and the Acute Kidney Injury Network (AKIN) criteria for kidney injury. A doubling of the serum creatinine level is correlated with RIFLE-I (injury to the kidney) and AKIN stage 2 [64].

AKI occurs in 12–21% of patients undergoing autologous HSCT and majorly depends on the type of conditioning used after allogenic HSCT. Myeloablative conditioning and reduced-intensity conditioning (RIC) are associated with 35–56% and 7–46% incidence of AKI [64–69]. Kidney replacement therapy requirement in autologous HSCT, myeloablative allogenic HSCT and RIC is 7%, 20–33% and 4%, respectively [70]. Not only AKI occurring within the first 30 days of HSCT, but also its severity portends an increased risk of death and overall low survival rates [64,71,72]. Among patients who require KRT, the mortality is exceedingly high (55–100%) [73,74].
7.1. Pathogenesis of HSCT-Related AKI

Hematopoietic stem cell transplantation can induce a myriad of pathophysiological changes in virtually all compartments of renal parenchyma (Figure 3).

![Figure 3. Pathogenesis of HSCT-associated AKI. HSCT = hematopoietic stem cell transplant, GVHD = graft vs. host disease, Glom = glomerular, MCD = minimal change disease, IgAN = IgA nephropathy, MPGN = membranoproliferative glomerulonephritis, FSGS = focal segmental glomerulosclerosis, PTCitis = peritubular capillaritis, CNI = calcineurin inhibitor, MTx = methotrexate, TLS = tumor lysis syndrome, HTN = Hypertension.](image)

7.2. Risk Factors and Etiology of HSCT-Related AKI

Traditional cardiovascular risk factors such as diabetes mellitus or hypertension predispose patients to develop AKI post-HSCT. However, there are transplant-specific factors in both myeloablative and non-myeloablative groups. These risk factors are along with various etiologies and their pathological phenotypes are outlined in Table 3.
Table 3. Risk factors, etiology and pathological phenotype of AKI in HSCT [70,75,76].

| Risk Factors for AKI Post HSCT | Etiologies of AKI | Pathology |
|--------------------------------|-------------------|-----------|
| **Prerenal**                   |                   | ATN       |
| Common Risk Factors            |                   | Acute HRS Physiology |
| Pre-HSCT DM                    | Dehydration       |           |
| Pre-HSCT HTN                   | ES                |           |
| Pre-HSCT Renal Impairment     | Sepsis            |           |
| Sepsis                         | Hepatic SOS       |           |
| Mechanical Ventilation         |                   |           |
| ICU Admission                  |                   |           |
| Myeloablative HSCT             |                   |           |
| Hepatic SOS                    |                   |           |
| Lung Toxicity                  |                   |           |
| High-Risk Disease              |                   |           |
| Acute GVHD                     |                   |           |
| CNI                            |                   |           |
| Non-Myeloablative HSCT         |                   |           |
| Prior Myeloablative HSCT       |                   |           |
| CMV Reactivation               |                   |           |
| High-Risk Disease              |                   |           |
| Acute GVHD                     |                   |           |
| CNI                            |                   |           |
| MTx                            |                   |           |
| Direct Nephrotoxicity          |                   |           |
| Drugs (Chemotherapy, Antimicrobials, CNI, MTx) | Tubulointerstitial Damage | ATN, Intraductular Obstruction due to Hemolysis from DMSO. |
| Marrow Transfusion Toxicity    |                   |           |
| Acute GVHD                     |                   |           |
| BK Virus & Adenovirus          |                   |           |
| Tumor Lysis Syndrome           | Intraductular Obstruction | ATN |
| Postrenal Obstruction          |                   |           |
| Retroperitoneal Fibrosis       |                   |           |
| Lymphadenopathy                |                   |           |
| Hemorrhagic Cystitis           |                   |           |
| BK Cystitis                    |                   |           |
| Adenovirus Cystitis            |                   |           |
| Glomerular                     | TA-TMA, MCD, MN, MPGN & FSGS Pattern | ATN |
| Ischemic Injury                |                   |           |
| Dehydration                    |                   |           |
| ES                             |                   |           |
| Sepsis                         |                   |           |
| Shock                          |                   |           |
| TA-TMA, MCD, MN, MPGN & FSGS Pattern | ATN |
| Tubulointerstitial Damage      |                   |           |
| ATN, Intraductular Obstruction due to Hemolysis from DMSO. | AIN |
| Hemolysis from DMSO.           |                   |           |

DM = diabetes mellitus, HSCT = hematopoietic stem cell transplant, HTN = hypertension, SOS = sinusoidal obstruction syndrome, GVHD = graft vs host disease, CNI = calcineurin inhibitor, CMV = cytomegalovirus, MTx = methotrexate, ES = engraftment syndrome, HRS = hepatorenal syndrome, TA-TMA = transplant associated thrombotic microangiopathy, MCD = minimal change disease, MPGN = membranoproliferative glomerulonephritis, MN = membranous nephropathy, FSGS = focal segmental glomerulosclerosis, ATN = acute tubular necrosis, DMSO = dimethyl sulfoxide.

8. Tumor Lysis Syndrome

Tumor lysis syndrome (TLS) is one of the most common oncological emergencies encountered in clinical practice.

8.1. Definition of TLS

Tumor lysis syndrome was defined by Hande-Garrow in 1993 and by Cairo-Bishop in 2004 [77,78], later modified by Howard and colleagues in 2011 [79]. Cairo-Bishop’s definition (Table 4) proposed specific laboratory criteria and grading for TLS [80,81].
Table 4. Cairo-Bishop’s definition for laboratory and clinical tumor lysis syndrome (TLS).

| Laboratory TLS | Clinical TLS |
|----------------|-------------|
| Two or More Laboratory Abnormalities from Day 3 up to Day 7, After Initiation of Cytotoxic Therapy: | Laboratory TLS Plus 1 or More of the Following: |
| Uric Acid ≥ 8 mg/dL | Creatinine ≥ 1.5 times the upper limit of normal (ULN) |
| Potassium ≥ 6 mEq/L | Cardiac Arrhythmia |
| Phosphate ≥ 6.5 mg/dl for Children or ≥ 4.5 mg/dl for Adults Calcium ≤ 7 mg/dL. OR | Seizure |
| 25% Change from Baseline in Any of the Above Values | Sudden Death |

Cairo Bishop Grading of Clinical Tumor Lysis Syndrome

| Complication | Grade |
|--------------|-------|
| Laboratory TLS | 0 | 1 | 2 | 3 | 4 | 5 |
| Creatinine | Absent | Present | Present | Present | Present | Present |
| <1.5 Times ULN | 1.5 Times ULN | 1.5 to 3.0 Times ULN | >3.0 to 6.0 Times ULN | >6.0 Times ULN | Death |
| Cardiac Arrhythmia | None | Intervention not Indicated | Nonurgent Medical Intervention Indicated | Symptomatic Despite Medications, Controlled with a Device (e.g., Defibrillator) | Life-Threatening and Associated with congestive heart failure Syncope, Shock | Death |
| Seizures | None | Not applicable | One Brief Generalized Seizure; Seizure(s) Well controlled by Anticonvulsants; Infrequent Focal Motor Seizures not Interfering with Activities of Daily Living | Seizure with Altered Consciousness; Poorly Controlled Seizure Disorder with Breakthrough Generalized Seizures Despite Medical Management | Intractable Seizure, Status Epilepticus | Death |

8.2. Epidemiology

The incidence of TLS is not well defined due to a lack of a universal definition, heterogeneous patient population, and differences in treatment strategies and prophylaxis. Bulky and rapidly proliferating tumors, as well as treatment-sensitive tumors are at high risk of TLS. Incidences of TLS, ranging from 4% to 53%, have been quoted in childhood hematological malignancies with acute lymphoblastic leukemia (ALL), Burkitt and diffuse large B-cell lymphoma carrying the highest risk [82]. Pre-treatment kidney failure (Sr creatinine > 1.4 mg/dL) strongly predicted TLS and clinical TLS was associated with higher mortality than lab TLS [83]. However, with the advent of newer and effective targeted therapies such as monoclonal antibodies, immunotherapy and drugs such as tyrosine kinase inhibitors, TLS has been reported in these low-risk tumors as well.

8.3. Risk Factors and Risk Assessment

Risk factors for developing TLS can be broadly classified into disease-related, patient-related and treatment related factors (Table 5).
Table 5. Risk Factors for Tumor Lysis Syndrome.

| Disease-related | Patient-related | Treatment-related |
|-----------------|-----------------|------------------|
| Rapid Cellular Proliferation (LDH >2-Time ULN) | Preexisting Renal Disease | Intensity of Cytoreductive Therapy (Single Agent Versus Combination, Disease Specific) |
| High Tumor Burden (Tumor >10 cm, metastatic disease, WBC >25 × 10⁷/µL) | Preexisting Hyperuricemia | Concomitant Use of Nephrotoxic Drugs |
| Sensitive to Cytoreductive Therapy | Hypovolemia | Inadequate Hydration During Treatment |
| Renal Infiltration or Outflow Tract Obstruction | Hypotension | |
| | Acidic Urine | |

8.4. Prevention and Treatment of Tumor Lysis Syndrome (TLS)

Tumor lysis syndrome can have dire complications; hence the International Panel on TLS recommends preventive and treatment strategies [80]. These strategies have been outlined in the infographic (Figure 4).

9. Obstructive Uropathy

Malignancies of the genitourinary tract commonly predispose to urinary tract obstruction. These commonly include cancer of the bladder, prostate, uterus and cervix. Obstruction typically occurs due to intratubular blockage or extrarenal obstruction by a tumor mass. Intratubular obstruction is commonly seen in lymphoproliferative malignancies and occurs due to crystals precipitating in tubules, e.g., uric acid, light chain casts, drug crystals, e.g., high dose methotrexate therapy, blood clots, among others. Extrarenal
obstruction commonly occurs in metastatic disease of gastrointestinal and genitourinary tracts, e.g., retroperitoneal tumor or fibrosis or enlarged lymph nodes, bladder obstruction due to cancer, urothelial cancer of ureter, post-radiation therapy (immediately due to blood clots or later due to fibrosis involving the ureteral orifices), BK virus infection in HSCT patients, etc.

Non-dilated obstructive uropathy is frequently missed as causative of AKI, and it is an underreported condition [84]. It is commonly seen in malignancies of pelvic areas where there is minimal or no dilatation of the proximal part of the urinary tract; however, percutaneous nephrostomy leads to rapid renal recovery. The possible causes for the non-dilatation of ureters are the encasement of the ureter with a tumor or fibrous tissue [85], abnormal ureteral peristalsis [86], ureteral edema [87,88] or simultaneous severe volume depletion. Hence, in unexplained renal failure in pelvic malignancies, obstructive uropathy must be ruled out even in the absence of pelvicalyceal system (PC)system dilatation on imaging.

Clinically, patients may be asymptomatic despite chronic urinary tract obstruction. Acute obstruction may lead to pain and hematuria. Urine output may persist unless complete bilateral ureteric obstruction occurs. Hence, the presence of urine does not rule out obstruction.

Imaging may show dilated ureter and collecting systems in one or both kidneys. Ultrasound is commonly carried out as the first imaging modality due to its easy availability and no radiation exposure. Alternatively, CT scan, MRI or nuclear imaging can also be used. Antegrade urography can establish the level of obstruction in patients who have nondiagnostic imaging studies.

Once diagnosed, percutaneous nephrostomy (PCN) or ureteral stents are used to relieve the obstruction. In a retrospective study of 102 patients who underwent decompression for ureteral obstruction, 68% had a bilateral obstruction. Stent or PCN placement was successful in 95% of cases, but more than 50% of patients developed complications such as urinary tract infection. The presence of metastasis and malignant ureteral obstruction in previously established malignancy were independent prognostic factors for inferior overall survival [89]. The median survival was less than seven months in such patients. Clinical judgement is required to decide which patients would benefit most from decompression with these invasive procedures [90]. A multidisciplinary decision-making process is highly recommended in cases with advanced malignancy.

10. Conclusions

Acute kidney injury is a global health problem and patients with cancer are more susceptible to it. The occurrence of AKI is a predictor of all-cause mortality in patients with cancer. Dramatic advances have occurred in management which has prolonged the longevity of life in patients with cancer. However, this comes at an expense, with an increase in the drug- and cancer-related adverse renal events. AKI can be due to cancer itself or as a complication of its treatment and poses a challenge to the health care personnel. The etiology is becoming increasingly complex and multifactorial, and a physician needs to keep an open-minded approach to treat these patients in an optimal manner. A systematic evaluation of the patient is essential to identify potential causes for AKI as it can have treatment and prognostic implications. Kidney biopsy must be considered whenever deemed safe, in unexplained AKI and in cases where immune-mediated renal injury is suspected.

The emergence of onco-nephrology as a subspecialty falls at an intersection of oncology and nephrology care. A multidisciplinary team is the need of the hour and should include an oncologist, nephrologist, dedicated nursing team, nutritionist, palliative care and primary care physician. The focus needs to be shifted to manage patients’ comorbidities such as diabetes, hypertension, dyslipidemia and cardiovascular disease, as these are known to predispose patients with cancer to AKI. The prevention of AKI is of paramount importance to prevent the downstream effects on the patient’s health. In the current era of
precision medicine, we are still in search of a perfect biomarker which could potentially predict AKI occurrence before the renal dysfunction sets in. With our increasing understanding of the pathophysiology of AKI in this niche population, hopefully the outcomes of patients suffering with cancer will improve and mitigate kidney-related adverse events.

**Author Contributions:** Equal contribution—Writing, reviewing and editing original draft—A.M.-M., A.L. and P.G. Supervision, review and editing—K.D.J., H.I. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** K.D.J. servers as a consultant for Astex pharmaceuticals and Natera.

**References**

1. Christiansen, C.F.; Johansen, M.B.; Langeberg, W.J.; Fryzek, J.P.; Sørensen, H.T. Incidence of Acute Kidney Injury in Cancer Patients: A Danish Population-based Cohort Study. *Eur. J. Intern. Med.* 2011, 22, 399–406. [CrossRef]

2. Kitchlu, A.; McArthur, E.; Amir, E. Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-based Cohort Study. *JNCL J. Natl. Cancer Inst.* 2019, 111, 727–736. [CrossRef]

3. Lameire, N.; Vanholder, R.; Van Biesen, W.; Benoit, D. Acute Kidney Injury in Critically Ill Cancer Patients: An Update. *Crit. Care 2016*, 20, 209. [CrossRef]

4. Cheng, Y.; Nie, S.; Li, L.; Li, Y.; Liu, D.; Xiong, M.; Wang, L.; Ge, S.; Xu, G.; EACH Study Investigators. Epidemiology and Outcomes of Acute Kidney Injury in Hospitalized Cancer Patients in China. *Int. J. Cancer 2019*, 144, 2644–2650. [CrossRef]

5. Lahoti, A.; Nates, J.L.; Wakefield, C.D.; Price, K.J.; Salahudeen, A.K. Costs and Outcomes of Acute Kidney Injury in Critically Ill Patients with Cancer. *J. Supportive Oncol. 2011*, 9, 149–155. [CrossRef] [PubMed]

6. Candrilli, S.; Bell, T.; Irish, W.; Morris, E.; Goldman, S.; Cairo, M.S. A Comparison of Inpatient Length of Stay and Costs among Patients with Hematologic Malignancies (Excluding Hodgkin Disease) Associated with and without Acute Renal Failure. *Clin. Lymphoma Myeloma 2008*, 8, 44–51. [CrossRef] [PubMed]

7. Lameire, N.; Van Biesen, W.; Vanholder, R. Acute Renal Problems in the Critically Ill Cancer Patient. *Curr. Opin. Crit. Care 2008*, 14, 635–646. [CrossRef] [PubMed]

8. Péne, F.; Percheron, S.; Lemiale, V. Temporal Changes in Management and Outcome of Septic Shock in Patients with Malignancies in the Intensive Care Unit. *Crit. Care Med. 2008*, 36, 690–696. [CrossRef]

9. Peigne, V.; Rusinová, K.; Karlin, L. Continued Survival Gains in Recent Years among Critically Ill Myeloma Patients. *Intensive Care Med. 2009*, 35, 512. [CrossRef]

10. Benoit, D.D.; Hoste, E.A. Acute Kidney Injury in Critically Ill Patients with Cancer. *Crit. Care Clin. 2010*, 26, 151–179. [CrossRef] [PubMed]

11. Darmon, M.; Ciroliti, M.; Thiery, G.; Schlemmer, B.; Azoulay, E. Clinical Review: Specific Aspects of Acute Renal Failure in Cancer Patients. *Crit. Care 2006*, 10, 211. [CrossRef]

12. Soares, M.; Salih, J.; Carvalho, M.S.; Darmon, M.; Rocco, J.R.; Specter, N. Prognosis of Critically Ill Patients with Cancer and Acute Renal Dysfunction. *J. Clin. Oncol. 2006*, 24, 4003–4010. [CrossRef] [PubMed]

13. Berghmans, T.; Meert, A.-P.; Markiewicz, E.; Sculier, J.-P. Continuous Venovenous Haemofiltration in Cancer Patients with Renal Failure: A Single-centre Experience. *Supportive Care Cancer 2004*, 12, 306–311.

14. Benoit, D.D.; Hoste, E.A.; Depuydt, P.O. Outcome in Critically Ill Medical Patients Treated with Renal Replacement Therapy for Acute Renal Failure: Comparison between Patients with and Those without Haematological Malignancies. *Nephrol. Dial. Transplant. 2005*, 20, 552–558. [CrossRef]

15. O’Reilly, M.; Mellotte, G.; Ryan, B.; O’Connor, A. Gastrointestinal Side Effects of Cancer Treatments. *Ther. Adv. Chronic Dis. 2020*, 11, 204062320970354. [CrossRef]

16. Nepal, S.; Dachsel, M.; Smallwood, N. Point-of-care Ultrasound Rapidly and Reliably Diagnoses Renal Tract Obstruction in Patients Admitted with Acute Kidney Injury. *Clin. Med. 2020*, 20, 541. [CrossRef]

17. Velez, J.C.Q.; Petkovich, B.; Karakala, N.; Huggins, J.T. Point-of-care Echocardiography Unveils Misclassification of Acute Kidney Injury as Hepatorenal Syndrome. *Am. J. Nephrol. 2019*, 50, 204–211. [CrossRef] [PubMed]

18. Beaubien-Souligny, W.; Denault, A.; Robillard, P.; Desjardins, G. The Role of Point-of-care Ultrasound Monitoring in Cardiac Surgical Patients with Acute Kidney Injury. *J. Cardiothorac. Vasc. Anesth. 2019*, 33, 2781–2796. [CrossRef]

19. O’Reilly, M.; Mellotte, G.; Ryan, B.; O’Connor, A. Gastrointestinal Side Effects of Cancer Treatments. *Ther. Adv. Chronic Dis. 2020*, 11, 204062320970354. [CrossRef]

20. Beaubien-Souligny, W.; Denault, A.; Robillard, P.; Desjardins, G. The Role of Point-of-care Ultrasound Monitoring in Cardiac Surgical Patients with Acute Kidney Injury. *J. Cardiothorac. Vasc. Anesth. 2019*, 33, 2781–2796. [CrossRef]

21. Burgio, G.; Martini, A. The Individuality of the Immune Response. *Scand. J. Rheumatol. 1987*, 16 (Suppl. 66), 5–11. [CrossRef] [PubMed]

22. Pargger, H.; Kaufmann, M.; Drop, L. Renal Vascular Hyperresponsiveness to Elevated Ionized Calcium in Spontaneously Hypertensive Rat Kidneys. *Intensive Care Med. 1998*, 24, 61–70. [CrossRef]
22. Lins, L.E. Reversible Renal Failure Caused by Hypercalcemia: A Retrospective Study. *Acta Med. Scand.* 1978, 203, 309–314. [CrossRef]
23. Rosner, M.H.; Dalkin, A.C. Onco-nephrology: The Pathophysiology and Treatment of Malignancy-associated Hypercalcemia. *Clin. J. Am. Soc. Nephrol.* 2012, 7, 1722–1729. [CrossRef]
24. Major, P.; Lortholary, A.; Hon, J. Zoledronic Acid is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials. *J. Clin. Oncol.* 2001, 19, 558–567. [CrossRef] [PubMed]
25. Anderson, K.; Ismail, N.; Flynn, P. Role of Bone-modifying Agents in Multiple Myeloma. *Br. J. Haematol.* 2001, 113, 11–17. [CrossRef] [PubMed]
26. Dietzek, A.; Connelly, K.; Cotugno, M.; Bartel, S.; McDonnell, A.M. Denosumab in Hypercalcemia of Malignancy: A Case Series. *J. Oncol. Pharm. Pract.* 2015, 21, 143–147. [CrossRef] [PubMed]
27. Adhikaree, J.; Newby, Y.; Sundar, S. RE: Denosumab for Patients with Persistent or Relapsed Hypercalcemia of Malignancy Despite Recent Bisphosphonate Treatment. *JNCI J. Natl. Cancer Inst.* 2015, 107. [CrossRef] [PubMed]
28. Hong, S.I.; Ahn, S.; Lee, Y.S. Contrast-induced Nephropathy in Patients with Active Cancer Undergoing Contrast-enhanced Computed Tomography. *Support Care Cancer* 2016, 24, 1011–1017. [CrossRef]
29. Mehran, R.; Dangas, G.D.; Weisbord, S.D. Contrast-Associated Acute Kidney Injury. *New Engl. J. Med.* 2019, 380, 2146–2155. [CrossRef]
30. Werner, S.; Bez, C.; Hinterleitner, C.; Horger, M. Incidence of Contrast-induced Acute Kidney Injury (CI-AKI) in High-risk Oncology Patients Undergoing Contrast-enhanced CT with a Reduced Dose of the Iso-osmolar Iodinated Contrast Medium Ioxidanol. *PloS ONE.* 2020, 15, e0233433. [CrossRef]
31. Parikh, C.R.; Liu, C.; Mor, M.K. Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the Preserve Trial. *Am. J. Kidney Dis.* 2020, 75, 187–194. [CrossRef]
32. Liu, C.; Mor, M.K.; Palevsky, P.M. Postangiography Increases in Serum Creatinine and Biomarkers of Injury and Repair. *Clin. J. Am. Soc. Nephrol.* 2020, 15, 1240–1250. [CrossRef]
33. Rudnick, M.R.; Leonberg-Yoo, A.K.; Litt, H.I.; Cohen, R.M.; Hilton, S.; Reese, P.P. The Controversy of Contrast-Induced Nephropathy With Intravenous Contrast: What Is the Risk? *Am. J. Kidney Dis.* 2020, 75, 105–113. [CrossRef] [PubMed]
34. Higgins, A.Y.; O’Halloran, T.D.; Chang, J.D. Chemotherapy-induced Cardiomyopathy. *Heart Fail. Rev.* 2015, 20, 721–730. [CrossRef] [PubMed]
35. Anand, I.S. Cardiorenal Syndrome: A Cardiologist’s Perspective of Pathophysiology. *Clin. J. Am. Soc. Nephrol.* 2013, 8, 1800–1807. [CrossRef] [PubMed]
36. Kazory, A.; Elkayam, U. Cardiorenal Interactions in Acute Decompensated Heart Failure: Contemporary Concepts Facing Emerging Controversies. *J. Card. Fail.* 2014, 20, 1004–1011. [CrossRef] [PubMed]
37. Mullens, W.; Damman, K.; Harjola, V.P. The Use of Diuretics in Heart Failure with Congestion - a Position Statement from the Heart Failure Association of the European Society of Cardiology. *Eur. J. Heart Fail.* 2019, 21, 137–155. [CrossRef]
38. Kazory, A.; Ronco, C. Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. *Cardiorenal Med.* 2019, 9, 1–7. [CrossRef] [PubMed]
39. Patel, D.M.; Connor, M.J., Jr. Intra-Abdominal Hypertension and Abdominal Compartment Syndrome: An Underappreciated Cause of Acute Kidney Injury. *Adv. Chronic Kidney Dis.* 2016, 23, 160–166. [CrossRef]
40. Pisoni, R.; Ruggenenti, P.; Remuzzi, G. Drug-induced Thrombotic Microangiopathy. *Drug Saf.* 2001, 24, 491–501. [CrossRef]
41. Moake, J.L. Thrombotic Microangiopathies. *New Engl. J. Med.* 2002, 347, 589–600. [CrossRef]
42. Kwaan, H.C.; Gordon, L.I. Thrombotic Microangiopathies in the Cancer Patient. *Acta Haematol.* 2001, 106, 52–56. [CrossRef]
43. Lohmann, H.-P.; Adam, W.; Heymer, B.; Kubanek, B. Microangiopathic Hemolytic Anemia in Metastatic Canceroma: Report of Eight Cases. *Ann. Intern. Med.* 1973, 79, 368–375. [CrossRef]
44. Brain, M.; Davie, J.; Hourihane, D.O.B. Microangiopathic Haemolytic Anaemia: The Possible Role of Vascular Lesions in Pathogenesis. *Br. J. Haematol.* 1962, 8, 358–374. [CrossRef] [PubMed]
45. Antman, K.H.; Skarin, A.T.; Mayer, R.J.; Hargreaves, H.K.; Canellos, G.P. Microangiopathic Hemolytic Anemia and Cancer: A Review. *Medicine* 1979, 58, 377–384. [CrossRef]
46. Lechner, K.; Obermeier, H.L. Cancer-related Microangiopathic Hemolytic Anemia: Clinical and Laboratory Features in 168 Reported Cases. *Medicine 2012,* 91, 195–205. [CrossRef]
47. George, J.N. Systemic Malignancies as a Cause of Unexpected Microangiopathic Hemolytic Anemia and Thrombocytopenia. *Cancer* 2011, 25, 908–914.
48. Elliott, M.A.; Letendre, L.; Gastineau, D.A.; Winters, J.L.; Pruthi, R.K.; Heit, J.A. Cancer-associated Microangiopathic Hemolytic Anemia with Thrombocytopenia: An Important Diagnostic Consideration. *Eur. J. Haematol.* 2010, 85, 43–50. [CrossRef] [PubMed]
49. Werner, T.L.; Agarwal, N.; Carney, H.M.; Rodgers, G.M. Management of Cancer-associated Thrombotic Microangiopathy: What is the Right Approach? *Am. J. Hematol.* 2007, 82, 295–298. [CrossRef] [PubMed]
50. Lesesne, J.B.; Rothschild, N.; Erickson, B. Cancer-associated Hemolytic-uremic Syndrome: Analysis of 85 Cases from a National Registry. *J. Clin. Oncol.* 1989, 7, 781–789. [CrossRef] [PubMed]
51. Cantrell, J.E., Jr.; Phillips, T.M.; Schein, P.S. Carcinoma-associated Hemolytic-uremic Syndrome: A Complication of Mitomycin C Chemotherapy. *J. Clin. Oncol.* 1985, 3, 723–734. [CrossRef] [PubMed]
81. Williams, S.M.; Killeen, A.A. Tumor Lysis Syndrome. *Arch. Pathol. Lab. Med.* 2019, 143, 386–393. [CrossRef] [PubMed]
82. Cairo, M.S.; Coiffier, B.; Reiter, A.; Younes, A. Recommendations for the Evaluation of Risk and Prophylaxis of Tumour Lysis Syndrome (TLS) in Adults and Children with Malignant Diseases: An Expert TLS Panel Consensus. *Br. J. Haematol.* 2010, 149, 578–586. [CrossRef] [PubMed]
83. Montesinos, P.; Lorenzo, I.; Martín, G. Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia: Identification of Risk Factors and Development of a Predictive Model. *Haematologica* 2008, 93, 67–74. [CrossRef]
84. Kocurek, J.N.; Orihuela, E.; Saltstein, D.R. Nondilated Obstructive Uropathy and Renal Failure as a Result of Carcinoma of the Intrapelvic Area. *Surg. Gynecol. Obstet.* 1991, 173, 470–472.
85. Rascoff, J.H.; Golden, R.A.; Spinowitz, B.S.; Charytan, C. Nondilated Obstructive Nephropathy. *Arch. Intern. Med.* 1983, 143, 696–698. [CrossRef] [PubMed]
86. Lalli, A.F. Retroperitoneal Fibrosis and Inapparent Obstructive Uropathy. *Radiology* 1977, 122, 339–342. [CrossRef] [PubMed]
87. Curry, N.S.; Gobien, R.P.; Schabel, S.I. Minimal-dilatation Obstructive Nephropathy. *Radiology* 1982, 143, 531–534. [CrossRef]
88. Spital, A.; Valvo, J.R.; Segal, A.J. Nondilated Obstructive Uropathy. *Urology* 1988, 31, 478–482. [CrossRef]
89. Loughlin, K.R.; Ganatra, A. Re: Malignant Ureteral Obstruction: Outcomes after Intervention. Have Things Changed? *J. Urol.* 2007, 178, 178–183. [CrossRef]
90. Folkard, S.S.; Banerjee, S.; Menzies-Wilson, R. Percutaneous Nephrostomy in Obstructing Pelvic Malignancy Does not Facilitate Further Oncological Treatment. *Int. Urol. Nephrol.* 2020, 52, 1625–1628. [CrossRef] [PubMed]